HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Heteronemin and tetrac derivatives suppress non-small cell lung cancer growth via ERK1/2 inhibition.

Abstract
The most common cancer, lung cancer, causes deaths worldwide. Most lung cancer patients have non-small cell lung carcinomas (NSCLCs) with a poor prognosis. The chemotherapies frequently cause resistance therefore search for new effective drugs for NSCLC patients is an urgent and essential issue. Deaminated thyroxine, tetraiodothyroacetic acid (tetrac), and its nano-analogue (NDAT) exhibit antiproliferative properties in several types of cancers. On the other hand, the most abundant secondary metabolite in the sponge Hippospongia sp., heteronemin, shows effective cytotoxic activity against different types of cancer cells. In the current study, we investigated the anticancer effects of heteronemin against two NSCLC cell lines, A549 and H1299 cells in vitro. Combined treatment with heteronemin and tetrac derivatives synergistically inhibited cancer cell growth and significantly modulated the ERK1/2 and STAT3 pathways in A549 cells but only ERK1/2 in H1299 cells. The combination treatments induce apoptosis via the caspases pathway in A549 cells but promote cell cycle arrest via CCND1 and PCNA inhibition in H1299 cells. In summary, these results suggest that combined treatment with heteronemin and tetrac derivatives could suppress signal transduction pathways essential for NSCLC cell growth. The synergetic effects can be used potentially as a therapeutic procedure for NSCLC patients.
AuthorsCheng-Chin Chung, Tung-Yung Huang, Hung-Ru Chu, Roberto De Luca, Elena Candelotti, Chi-Hung Huang, Yu-Chen S H Yang, Sandra Incerpi, Jens Z Pedersen, Chi-Yu Lin, Haw-Ming Huang, Sheng-Yang Lee, Zi-Lin Li, Chun A ChangOu, Wen-Shan Li, Paul J Davis, Hung-Yun Lin, Jacqueline Whang-Peng, Kuan Wang
JournalFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association (Food Chem Toxicol) Vol. 161 Pg. 112850 (Mar 2022) ISSN: 1873-6351 [Electronic] England
PMID35151786 (Publication Type: Journal Article)
CopyrightCopyright © 2022 Elsevier Ltd. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Terpenes
  • heteronemin
  • Extracellular Signal-Regulated MAP Kinases
  • tetraiodothyroacetic acid
  • Thyroxine
Topics
  • Antineoplastic Agents (pharmacology)
  • Carcinoma, Non-Small-Cell Lung (drug therapy)
  • Cell Line, Tumor
  • Drug Therapy, Combination
  • Extracellular Signal-Regulated MAP Kinases (genetics, metabolism)
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Lung Neoplasms (drug therapy)
  • Terpenes (pharmacology)
  • Thyroxine (analogs & derivatives, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: